COMPANY
Young Therapeutics, LLC
Funding and NIH signals
- NIH award NIH awarded $1.49M (SBIR Phase II 5R44HL160338-03, continuation, notice Jun 30, 2026). NIH RePORTER 5R44HL160338-03 (Jun 30, 2026)
Evidence (1 event)
- Jun 30, 2026 · NIH RePORTER 5R44HL160338-03
Organization: YOUNG THERAPEUTICS, LLC; City/State: PHILADELPHIA, PA; Project number: 5R44HL160338-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1488899; Administering IC: National Heart Lung and Blood Institute; Project title: Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.; Organization type: Domestic For-Profits
- Jun 30, 2026 · NIH RePORTER 5R44HL160338-03
Timeline
- Grant Government grant — SBIR: $1.49M (annual award, as published), announced Jun 30, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
- Grant Government grant — SBIR: $1.49M (annual award, as published), announced Mar 31, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
Funding
NIH awards 3
- NIH award 1R43HL160338-01 FY2021: $560,261 awarded for that fiscal year; activity R43 (SBIR); PI YOUNG, LINDON H; recipient as written: YOUNG THERAPEUTICS, LLC, PHILADELPHIA, PA. Young, Lindon H source ↗
- NIH award 3R43DK121626-01A1S1 FY2020: $51,000 awarded for that fiscal year; activity R43 (SBIR); PI YOUNG, LINDON H; recipient as written: YOUNG THERAPEUTICS, LLC, PHILADELPHIA, PA. The effects of protein kinase C ep source ↗
- NIH award 1R43DK121626-01A1 FY2019: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI YOUNG, LINDON H; recipient as written: YOUNG THERAPEUTICS, LLC, PHILADELPHIA, PA. The effects of protein kinase C eps source ↗